Pharmacological treatment of obesity;Tratamiento farmacológico de la obesidad

Revista Espanola de Obesidad

Volumn 3, Issue 1, 2005, Pages 13-25

  Romero Ramos, H ^a   Martinez Brocca M A ^a   Pereira Cunill, J L ^a   Garcia Luna P P ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; CAFFEINE; DEXFENFLURAMINE; EPHEDRINE; FENFLURAMINE; GHRELIN; LEPTIN; MONOACYLGLYCEROL; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SIBUTRAMINE; SUCROSE POLYESTER; TERTIARY AMINE; TETRAHYDROLIPSTATIN; THYROID HORMONE; TRIACYLGLYCEROL; TRIACYLGLYCEROL LIPASE;

APPETITE; BASAL METABOLIC RATE; DOSE RESPONSE; DRUG INHIBITION; DRUG TOLERABILITY; ENERGY BALANCE; FAT INTAKE; FOOD AND DRUG ADMINISTRATION; HEALTH ECONOMICS; HUMAN; HUNGER; HYDROLYSIS; LIPID ABSORPTION; LIPOLYSIS; LOW CALORY DIET; OBESITY; PHYSICAL ACTIVITY; PREVALENCE; REVIEW; SATIETY; SEROTONIN RELEASE; SPAIN; THERMOGENESIS; VALVULAR HEART DISEASE; WEIGHT REDUCTION;

EID: 33646890006     PISSN: 16966112     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (91)

1. Foz M. Obesidad. Endocrinología 1992; 8: 339-44.
2. Bray GA. Barriers to the treatment of obesity. Ann Intern Med 1991; 115: 152-3.
3. Estudio prospectivo delphi. Costes sociales y económicos de la obesidad y sus patologías asociadas. Madrid: Gabinete de estudios Bernard Krief, 1999.
4. Pereira JL, García Luna PP, Astorga R. Luces y sombras en la cirugía de la obesidad. Rev Clin Esp 2003; 203: 567-9.
5. Alastrue A, Formiguera J, Rull M, et al. Cirugía bariátrica: Gastroplastia vertical anillada (GVA). Obesidad mórbida y superobesidad. Resultados antropométricos. Complicaciones técnicas y reintervenciones a largo plazo. Endocrinología 1992; 39: 365-75.
6. Alastrué A, Rull M, Formiguera J, Casas D, Fernández J, Broggi MA. Obesidad severa; tratamiento quirúrgico en 120 pacientes. Resultados y enfoque prospectivo. Nutr Hosp 1993; 7: 411-23.
7. Halpern A, Mancini MC. Treatment of obesity: an update on anti-obesity medications. Obes Rev 2003; 4: 25-42.
8. Munro JK, Ford M. Drug treatment of obesity. En: Silverstone T (ed). Drug and Appetite. Academic Press: London, 1982, pp 125-57.
9. Carlsson A. Amphetamine and brain catecholamines. En: Costa E and Garattini S (ed). Amphetamine and related compounds. Raven Press: New York, 1970, pp. 289-300.
10. Silverstone T. Appetite suppresants. A review. Drugs 1992; 43: 820-36.
11. Yanovski SZ, Yanovski JA. Drug therapy: Obesity. N Engl J Med 2002; 346: 591-602.
12. Kernan WN, Viscoli CM, Brass LM, Broderick JP, Brott T, Feldmann E, et al. Phenilpropanolamine and the risk of hemorragic stroke. N Engl J Med 2000; 343: 1826-32.
13. Michelson D, Amsterdam JD, Quitkin FM, Reimherr FW, Rosenbaum JF, Zajecka J, et al. Changes in weight during a 1-year trial of fluoxetine. Am J Psychiatry 1999; 156: 1170-6.
14. Goldstein DJ, Rampey AH Jr, Enas GG, Potvin JH, Fludzinski LA, Levine LR. Fluoxetine: a randomized clinical trial in the treatment of obesity. Int J Obes 1994; 18: 129-35.
15. Wadden TA, Bartlett SJ, Foster GD, Greenstein RA, Wingate BJ, Stunkard AJ, et al. Sertraline and relapse prevention training following treatment by very-low-calorie diet: a controlled clinical trial. Obes Res 1995; 3: 549-57.
16. McMurray J, Bloomfield P, Miller HC. Irreversible pulmonary hypertension after treatment with fenfluramine. BMJ 1986; 292: 239-40.
17. Brenot F, Herve P, Petitpretz P, Parent F, Duroux P, Simonneau G. Primary pulmonary hypertension and fenfluramine use. Br Heart J 1993; 70: 537-41.
18. Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996; 335: 609-16.
19. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997; 337: 581-8.
20. Khan MA, Herzog CA, Peter JV, Hartley GG, Madlon-Kay R, Dick CD, et al. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-supressant drugs. N Engl J Med 1998; 339: 713-8.
21. Wee CC, Phillips RS, Aurigemma G, Erban S, Kriegel G, Riley M, et al. Risk of valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication. Ann Intern Med 1998; 129: 870-4.
22. García Luna PP, Pereira Cunill JL, López Pardo F, Astorga R. Seguridad cardíaca y sibutramina. Med Clin 2002; 119: 356-9.
23. Pereira JL, López-Pardo F, Parejo J, Astorga R, Rodríguez-Puras MJ, García Luna PP. Study of heart valve function on obese patients treated with sibutramine. Med Clin 2002; 118: 57-9.
24. Hanotin C, Thomas F, Jones SP, Leutenegger E, Drouin P. Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study. Int J Obes 1998; 22: 32-8.
25. Bray GA, Blackburn GL, Ferguson JM, Greenway FL, Jain AK, Mendel CM, et al. Sibutramine produces dose-related weight loss. Obes Res 1999; 7: 189-8.
26. Padwal R, Li SK, Lau DCW. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomised controlled trials. Int J Obes 2003; 27: 1437-46.
27. Weigle DS. Pharmacological therapy of obesity: Past, present, and future. J Clin Endocrinol Metab 2003; 88: 2462-9.
28. Smith IG, on behalf of the members of the Sibutramine Clinical Study 1047 Team; Goulder MA. Randomized placebo-controlled trial of long-term treatment with sibutramine in mild-to-moderate obesity. J Fam Pract 2001; 50: 505-12.
29. Apfelbaum M, Vague P, Ziegler O, Hanotin C, Thomas F, Leutenegger E. Long-term maintenance of weight loss after a very-low-calorie diet: a randomised blinded trial of the efficacy and tolerability of sibutramine. Am J Med 1999; 106: 179-84.
30. James WPT, Astrup A, Finer N, Hilsted J, Kopelman P, Rössner S, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. Lancet 2000; 356: 2119-25.
31. McMahon FG, Fujioka K, Singh BN, Mendel CM, Rowe E, Rolston K, et al. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. Arch Intern Med 2000; 160: 2185-91.
32. Fujioka K, Seaton TB, Rowe E, Jelinek CA, Raskin P, Lebovitz HE, et al. Sibutramine/Diabetes Clinical Study Group. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with Type 2 diabetes mellitus. Diabetes Obes Metab 2000; 2: 175-87.
33. Gokcel A, Karakose H, Ertorer EM, Tanci N, Tutuncu NB, Guvener N. Effects of sibutramine in obese female subjects with type 2 diabetes mellitus and poor blood glucose control. Diabetes Care 2001; 24: 1957-60.
34. Hansen D, Astrup A, Toubro S, Finer N, Kopelman P, Hilsted J, et al. Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity. Results from the European multi-centre STORM trial. Int J Obes 2001; 25: 496-501.
35. Wirth A, Krause J. Long-term weight loss with sibutramine-a randomized controlled trial. JAMA 2001; 286: 1331-9.
36. Schwimmer JB, Burwinkle TM, Varni JW. Health-related quality of life of severely obese children and adolescents. JAMA 2003; 289: 1813-9.
37. Berkowitz RI, Wadden TA, Tershakovec AM, Cronquist JL. Behaviour therapy and sibutramine for the treatment of adolescent obesity. JAMA 2003; 289: 1805-12.
38. Leeds AR. Dietary fibre: mechanisms of action. Int J Obes 1987; 11 (Suppl. 1): 27-31.
39. Evans E, Miller DS. Bulking agents in the treatment of obesity. Nutr Metab 1975; 18: 199-203.
40. Jenkins DJ, Goof DV, Leeds AR, Alberti KG, Wolever TM, Gassull MA, et al. Unabsorbable carbohydrates and diabetes: decreased post-prandial hyperglycaemia. Lancet 1976; 2: 172-4.
41. Guerciolini R. Mode of acting of orlistat. Int J Obes 1997; 21 (Supl. 1): 12S-23S
42. Reitsma JB, Castro Cabezas M, de Bruin TW, Erkelens DW. Relationship between improved postprandial lipemia and low-density lipoprotein metabolism during treatment with tetrahydrolipstatin, a pancreatic lipase inhibitor. Metabolism 1994; 43: 293-8.
43. Zhi J, Melia AT, Eggers H, Joly R, Patel IH. Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers. J Clin Pharmacol 1995; 35: 1103-8.
44. Heck AM, Yanovski JA, Calis KA. Orlistat a new lipase inhibitor for the management of obesity. Pharmacotherapy 2000; 20: 270-9.
45. Davidson MH, Hauptman J, Di Girolano M. Weight control and risk factor reduction in obese subjects treated for two years with orlistat: a randomized controlled trial. JAMA 1999; 281: 235-42.
46. Sjostrom L, Rissanen A. Randomised placebo controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998; 352: 167-72.
47. Hollander PA, Elbstein SC, Hirsch IB. Role of orlistat in the treatment of obese patients with diabetes type 2:1 year randomised double-blind study. Diabetes Care 1998; 21: 1288-94.
48. Kelley DE, Kuller LH, McKolanis TM, Harper P, Mancino J, Kalhan S. Effects of moderate weight loss and orlistat on insulin resistance, regional adiposity, and fatty acids in type 2 diabetes. Diabetes Care 2004; 27: 33-40.
49. Drent MI, Larsson I, William-Olsson T. Orlistat (RO-18-0647), a lipase inhibitor in the treatment of human obesity; a multiple dose study. Int J Obes 1995; 19: 221-6.
50. Salvador, Silva C, Santos E. Tratamiento farmacológico de la obesidad. J Ann Sist San Navarra 2002; 25 (Suppl. 1): 143S-51S.
51. Mc Duffie JR, Calis KA, Uwaifo GI, Sebring NG, Fallon EM, Habbard VS, et al. Three months tolerability of orlistat in adolescents with obesity-related comorbid conditions. Obes Res 2002; 10: 642-50.
52. Norgren S, Danielsson P, Jurold R, Lötborn M, Marcus C. Orlistat treatment in obese prepuberal children: a pilot study. Act Paediatr 2003; 92: 666-70.
53. Zhi J, Moore R, Kanitra L. The effect of short term (21 day) orlistat treatment on the physiologic balance of six selected macrominerals and microminerals in obese adolescents. J Am Col Nutr 2003; 22: 357-62.
54. Rolls BJ, Pirraglia PA, Jones MB, Peters JC. Effects of olestra, a noncaloric fat substitute, on daily energy and fat intakes in lean men. Am J Clin Nutr 1992; 56: 84-92.
55. Bray GA, Sparti A, Windhauser MM, York DA. Effects of two weeks fat replacement by olestra on food intake and energy metabolism. FASEB J 1995; 9: A439.
56. Roy J, Lovejoy J, Windhauser MM, Bray GA. Metabolic effects of fat substitution with olestra. FASEB J 1995; 11: 358A.
57. Bayraktar F, Hamulu F, Ozgen AG, Yilmaz C, Tüzün M, Kabalak T. Acarbose treatment in obesity: a controlled study. Eat Weight Disord 1998; 3: 46-9.
58. Bessard T, Schutz Y, Yequier E. Energy expenditure and postprandial thermogenesis in obese women before and after weight loss. Am J Clin Nutr 1983; 8: 680-94.
59. Segal KR, Presta E, Gutin B. Thermic effect of food during graded exercise in normal weight and obese men. Am J Clin Nutr 1984; 40: 995-1000
60. Danforth E Jr, Horton ES, O'Connell M, Sims EA, Burger AG, Ingbar SH, et al. Dietary-induced alterations in thyroid hormone metabolism during overnutrition. J Clin Invest 1979; 64: 1336-47.
61. Moore R, Grant AM, Howard AN, Mills IH. Treatment of obesity with triiodothyronine and a very-low-calorie diet. Lancet 1980; 1: 223-6.
62. Koppeschaar HPF, Meinders AE, Schwarz F. Metabolic response in grossly obese subjects treated with a very-low-calorie diet with and without triiodothyronine treatment. Int J Obes 1983; 7: 133-41.
63. Anónimo. La peligrosa moda de las fórmulas antiobesidad. Boletín Terapeútico Andaluz 1990; 7: 45-7.
64. Gibbs HR. Diet pills and sudden death (letter). N Engl J Med 1988; 318: 1127.
65. Levin BE, Triscari J, Sullivan AC. Relationship between sympathetic activity and diet-induced obesity in two rats strains. Am J Physiol 1983; 245: 367-71.
66. Munger R, Bückert A, Jéquier E, Felber JP. Thermogenic effect of the new β-adrenoreceptor agonist Ro 40-2148 in healthy male volunteers. Diabetes 1990; 39 (Suppl. 1): 284 (abstr).
67. Arner P. Adrenergic receptor function in fat cells. Am J Clin Nutr 1992; 55 (Suppl. 1): 228-36.
68. Cawthorne MA, Smith SA, Young P. Effect of thermogenic drugs on insulin sensitivity and glucose utilization by brown adipose tissue. En: Berry EM, Blondheim SH, Elinhou HE, Shafrir E (ed). Recent advances in obesity research V. John Libbey: London, 1987, pp. 312-18.
69. Dulloo AG, Miller DS. Prevention of genetic fa/fa obesity with an ephedrine-methylxantines thermogenic mixture. Am J Physiol 1987; 252: 507-13.
70. Toubro S, Astrup AV, Breum L, Quaade F. Safety and efficacy of long-term treatment with ephedrine, caffeine and an ephedrine/caffeine mixture. Int J Obes 1993; 17 (Suppl. 1): 69-72.
71. Daly PA, Krieger DR, Dulloo AG, Young JB, Landsberg L. Ephedrine, caffeine and aspirin: safety and efficacy for treatment of human obesity. Int J Obes 1993; 17 (Suppl 1): 73-8.
72. Shekelle PG, Hardy ML, Morton SC, Maglione M, Mojica WA, Suttorp MJ, et al. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis. JAMA 2003; 289: 1537-45.
73. McBride BF, Karapanos AK, Krudysz A, Kluger J, Coleman CI, White CM. Electrocardiographic and hemodynamic effects of a multicomponent dietary supplement containing ephedra and caffeine. A randomized controlled trial. JAMA. 2004; 291: 216-21.
74. Jéquier E, Munger R, Felber JP. Thermogenic effects of various β-adrenoreceptor in humans: their potential usefulness in the treatment of obesity. Am J Clin Nutr 1992; 55 (Suppl. 1): 249-51.
75. Schwartz MW, Woods SC, Porte Jr D, Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature 2000; 404: 661-71.
76. Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, Weigle DS. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 2001; 50: 1714-9.
77. Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, et al. Effects or recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 1999; 341: 879-84.
78. Heymsfield SB, Greenberg AS, Fujioka K, Dixon RM, Kushner R, Hunt T, et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 1999; 282: 1568-75.
79. Cummings DE, Weigle DS, Frayo RS, Breen PA, Ma PK, Dellinger EP, et al. Plasma ghrelin levels after diet-induced weight loss or gastric by-pass surgery. N Engl J Med 2002; 346: 1623-30.
80. Delparigi A, Tschöp M, Heiman ML, Salbe AD, Vozarova B, Sell SM, et al. High circulating ghrelin: a potential cause for hyperphagia and obesity in Prader-Willi syndrome. J Clin Endocrinol Metab 2002; 87: 5461-4.
81. Guler HP, Ettinger MP, Littlejonh TW. Axokine causes significant weight loss in severely and morbidly obese subjects. Int J Obes 2001; 25 (Suppl. 2): S111.
82. Henny C, Bückert A, Schutz Y, Jéquier E, Felber JP. Comparison of thermogenic activity induced by the new sympathomimetic Ro 16-8714 between normal and obese subjects. Int J Obes 1988; 12: 227-36.
83. Connacher AA, Jung RT, Mitchell PEG. Weight loss in obese subjects on a restricted diet given BRL 26830A, a new atypical β adrenoreceptor agonist. BMJ 1988; 296: 1217-20.
84. Zed CA, Harris GA, Harrison PJ, et al. Anti-obesity activity of a novel β-adrenoreceptor agonist (BRL 26830A) in diet-restricted obese subjects. Int J Obes 1985; 9: 231A.
85. Chapman BJ, Farquahar DL, Galloway SM, Simpson GK, Munro JF. The effects of a new beta-adrenoreceptor agonist BRL 26830A in refractory obesity. Int J Obes 1988; 12: 119-23.
86. Munger R, Bückert A, Jéquier E, Felber JP. Thermogenic effect of the new β-adrenoreceptor agonist Ro 40-2148 in healthy male volunteers. Diabetes 1990; 39 (Suppl. 1): 284A.
87. Cawthorne MA, Sennitt MV, Arch JRS, Smith SA. BRL35135, a potent and selective atypical β-adrenoreceptor agonist. Am J Clin Nutr 1992; 55 (Suppl. 1): 252-7.
88. Holloway BR, Howe R, Rao BS, Stribling D. ICI D7114: a novel selective adrenoreceptor agonist of brown fat and thermogenesis. Am J Clin Nutr 1992; 55 (Suppl. 1): 262-4.
89. Berlan M, Galitzky J, Riviére D, Foureau M, Tran MA, Flores R, et al. Plasma cathecolamine levels and lipid mobilization induced by yohimbine in obese and non-obese women. Int J Obes 1991; 15: 305-15.
90. Editorial. Phytochemicals fighting fat. Diabet Obes Metab 2001; 3: 382.
91. Alemany M. Fernández López JA, Petrobelli A, Granada M, Foz M, Remesar X. Pérdida de peso en un paciente con obesidad mórbida en tratamiento con oleoil-estrona. Med Clin (Barc) 2003; 121: 496-9.